ophthalmologyОфтальмологияOphthalmology in Russia1816-50952500-0845Ophthalmology10.18008/1816-5095-2025-1-169-174ophthalmology-2596Research ArticleКЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯCLINICAL STUDIESПаттерны фовеальной эверсии у больных с диабетическим макулярным отекомPatterns of Foveal Eversion in Patients with Diabetic Macular Edemahttps://orcid.org/0009-0003-4798-6874СантороЭ. Ю.SantoroE. Yu.

Санторо Элина Юрьевна, кандидат медицинских наук, заведующая офтальмологическим отделением, доцент кафедры хирургических болезней СурГУ

ул. Энергетиков, 24/2, Сургут, 628408

пр. Ленина, 1, Сургут, 628412

Santoro Elina Yu., PhD, ophthalmologist, head of Ophthalmological department

Energetikov str., 24/2, Surgut, 628408

Lenina str., 1, Surgut, 628412

lina_urivaeva@mail.ruКинчинаИ. В.KinchinaI. V.

Кинчина Ирина Владимировна, врач-офтальмолог

ул. Энергетиков, 24/2, Сургут, 628408

Kinchina Irina V., ophthalmologist

Energetikov str., 24/2, Surgut, 628408

БУ «Сургутская окружная клиническая больница»; БУ ВПО Ханты-Мансийского автономного округа — Югры «Сургутский государственный университет»РоссияSurgut District Clinical Hospital; Surgut State UniversityRussian FederationБУ «Сургутская окружная клиническая больница»РоссияSurgut District Clinical HospitalRussian Federation202531032025221169174Copyright © Санторо Э.Ю., Кинчина И.В., 20252025Санторо Э.Ю., Кинчина И.В.Santoro E.Y., Kinchina I.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.ophthalmojournal.com/opht/article/view/2596

Цель: изучение влияния биомаркера фовеальной эверсии на морфологические и функциональные результаты лечения диабетического макулярного отека (ДМО).Материалы и методы. Проведен ретроспективный анализ историй болезней пациентов, получавших лечение ДМО в БУ «Сургутская окружная клиническая больница» в период с 2019 по 2024 год. Всем больным проводилось стандартное офтальмологическое обследование.Результаты. Всего для исследования были изучены истории болезни 20 больных (25 глаз) с наличием при инициации терапии фовеальной эверсии. Исходная МКОЗ в среднем составляла 0,35, центральная толщина сетчатки (ЦТС) на старте терапии — в среднем 720 мкм. Количество инъекций ингибитора ангиогенеза и имплантаций дексаметазона в первый год терапии составляло 7,5 и 1 соответственно. В конце срока наблюдения средняя ЦТС составляла 310 мкм, а МКОЗ колебалась от 0,2 до 0,7, в среднем 0,43.Заключение. Наличие биомаркера фовеальной эверсии является прогностически неблагоприятным фактором и сопряжено с высокой вероятностью развития персистирующего ДМО и неудовлетворительными морфофункциональными результатами лечения.

The purpose of our work was to study the influence of the biomarker of foveal eversion on the morphological and functional results of treatment of DME.Materials and methods. A retrospective analysis of medical records of patients who received treatment for DME at the Surgut District Clinical Hospital in the period from 2019 to 2024 was carried out. All patients underwent a standard ophthalmological examination.Results. A total of 20 patients (25 eyes) with foveal eversion at the initiation of therapy were recruited for the study. Baseline BCVA averaged 0.35. The CRT at the start of therapy averaged 720 µ m. The number of aflibercept injections and dexamethasone implantations in first year of therapy was 7.5 and 1, respectively. At the end of the observation period, the average CRT was 310 μm, and BCVA ranged from 0.2 to 0.7, with an average of 0.43.Conclusion. The presence of a biomarker of foveal eversion is an unfavorable prognostic factor and is associated with a high probability of developing persistent DME and unsatisfactory morphofunctional treatment results.

диабетический макулярный отекоптическая когерентная томографиябиомаркерыфовеальная эверсияdiabetic macular edemaoptical coherence tomographybiomarkersfoveal eversionReferencesАстахов ЮС, Шадричев ФЕ. Диабетологические центры — новый этап в создании специализированной помощи больным с диабетической ретинопатией. Клиническая офтальмология. 2001;4:148–153.Astahov YuS, Shadrischev FE, Diabetologic centers — a new step in creation of specialized help for patients with diabetic retinopathy. Clinical Ophthalmology. 2001;4:148–153 (In Russ.).Дедов ИИ, Шестакова МВ, Майоров АЮ, Викулова ОК, Галстян ГР, Кураева ТЛ, Петеркова ВА, Смирнова ОМ, Старостина ЕГ, Суркова ЕВ, Сухарева ОЮ, Токмакова АЮ, Шамхалова МШ, Ярек-Мартынова ИР, Артемова ЕВ, Бешлиева ДД, Бондаренко ОН, Волеводз НН, Григорян ОР, Гомова ИС, Джемилова ЗН, Есаян РМ, Ибрагимова ЛИ, Калашников ВЮ, Кононенко ИВ, Лаптев ДН, Липатов ДВ, Мотовилин ОГ, Никонова ТВ, Роживанов РВ, Шестакова ЕА. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова 9-й выпуск. Сахарный диабет. 2019;22(1S1):1–144.Dedov II, Shestakova MV, Mayorov AYu, Vikulova OK, Galstyan GR, Kuraeva TL, Peterkova VA, Smirnova OM, Starostina EG, Surkova EV, Sukhareva OYu, Tokmakova AYu, Shamkhalova MS, Jarek-Martynova IR, Artemova EV, Beshlieva DD, Bondarenko ON, Volevodz NN, Grigoryan OR, Gomova IS, Dzhemilova ZN, Esayan RM, Ibragimova LI, Kalashnikov VYu, Kononenko IV, Laptev DN, Lipatov DV, Motovilin OG, Nikonova TV, Rozhivanov RV, Shestakova EA. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV, Mayorov AYu. 9th edition. Diabetes mellitus. 2019;22(1S1):1–144 (In Russ.). doi: 10.14341/DM221S1.Maturi RK, Glassman AR, Liu D, Beck RW, Bhavsar AR, Bressler NM, Jampol LM, Melia M, Punjabi OS, Salehi-Had H, Sun JK; Diabetic Retinopathy Clinical Research Network. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial. JAMA Ophthalmol. 2018 Jan 1;136(1):29–38. doi: 10.1001/jamaophthalmol.2017.4914.Maturi RK, Glassman AR, Liu D, Beck RW, Bhavsar AR, Bressler NM, Jampol LM, Melia M, Punjabi OS, Salehi-Had H, Sun JK; Diabetic Retinopathy Clinical Research Network. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial. JAMA Ophthalmol. 2018 Jan 1;136(1):29–38. doi: 10.1001/jamaophthalmol.2017.4914.Lazic R, Lukic M, Boras I, Draca N, Vlasic M, Gabric N, Tomic Z. Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant. Retina. 2014 Apr;34(4):719–724. doi: 10.1097/IAE.0b013e3182a48958.Lazic R, Lukic M, Boras I, Draca N, Vlasic M, Gabric N, Tomic Z. Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant. Retina. 2014 Apr;34(4):719–724. doi: 10.1097/IAE.0b013e3182a48958.Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM; Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014 Oct;121(10):1904–1914. doi: 10.1016/j.ophtha.2014.04.024.Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM; Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014 Oct;121(10):1904–1914. doi: 10.1016/j.ophtha.2014.04.024.Bressler NM, Beaulieu WT, Glassman AR, Blinder KJ, Bressler SB, Jampol LM, Melia M, Wells JA 3rd; Diabetic Retinopathy Clinical Research Network. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2018 Mar 1;136(3):257–269. doi: 10.1001/jamaophthalmol.2017.6565.Bressler NM, Beaulieu WT, Glassman AR, Blinder KJ, Bressler SB, Jampol LM, Melia M, Wells JA 3rd; Diabetic Retinopathy Clinical Research Network. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2018 Mar 1;136(3):257–269. doi: 10.1001/jamaophthalmol.2017.6565.Bressler SB, Ayala AR, Bressler NM, Melia M, Qin H, Ferris FL 3rd, Flaxel CJ, Friedman SM, Glassman AR, Jampol LM, Rauser ME; Diabetic Retinopathy Clinical Research Network. Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment. JAMA Ophthalmol. 2016 Mar;134(3):278–285. doi: 10.1001/jamaophthalmol.2015.5346.Bressler SB, Ayala AR, Bressler NM, Melia M, Qin H, Ferris FL 3rd, Flaxel CJ, Friedman SM, Glassman AR, Jampol LM, Rauser ME; Diabetic Retinopathy Clinical Research Network. Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment. JAMA Ophthalmol. 2016 Mar;134(3):278–285. doi: 10.1001/jamaophthalmol.2015.5346.Будзинская МВ, Фурсова АЖ, Педанова ЕК. Специфические биомаркеры ответа на антиангиогенную терапию. Вестник офтальмологии. 2020;136(2):117–124.Budzinskaya MV, Fursova AZh , Pedanova EK. Specific biomarkers of response to antiangiogenic therapy. Vestn Oftalmol. 2020;136(2):117–124 (In Russ.). doi: 10.17116/oftalma2020136021117.Arrigo A, Aragona E, Capone L, Lattanzio R, Zollet P, Bandello F. Foveal eversion: A possible biomarker of persistent diabetic macular edema. Ophthalmol Ther. 2021;10(1):115–126. doi: 10.1007/s40123-020-00324-z.Arrigo A, Aragona E, Capone L, Lattanzio R, Zollet P, Bandello F. Foveal eversion: A possible biomarker of persistent diabetic macular edema. Ophthalmol Ther. 2021;10(1):115–126. doi: 10.1007/s40123-020-00324-z.Borrelli E, Barresi C, Feo A, GariG,Grosso D, Querques L, Sacconi R, Bandello F, Querques G. Imaging biomarkers and clinical factors associated with the rate of progressive inner and outer retinal thinning in patients with diabetic macular edema. Sci Rep. 2023 Feb 24;13(1):3224. doi: 10.1038/s41598-023-30432-2.Borrelli E, Barresi C, Feo A, GariG,Grosso D, Querques L, Sacconi R, Bandello F, Querques G. Imaging biomarkers and clinical factors associated with the rate of progressive inner and outer retinal thinning in patients with diabetic macular edema. Sci Rep. 2023 Feb 24;13(1):3224. doi: 10.1038/s41598-023-30432-2.Markan A, Agarwal A, Arora A, Bazgain K, Rana V, Gupta V. Novel imaging biomarkers in diabetic retinopathy and diabetic macular edema. Ther Adv Ophthalmol. 2020 Sep 4;12:2515841420950513. doi: 10.1177/2515841420950513.Markan A, Agarwal A, Arora A, Bazgain K, Rana V, Gupta V. Novel imaging biomarkers in diabetic retinopathy and diabetic macular edema. Ther Adv Ophthalmol. 2020 Sep 4;12:2515841420950513. doi: 10.1177/2515841420950513.Felfeli T, Katsnelson G, Kiss A, Plumptre L, Paterson JM, Ballios BG, Mandelcorn ED, Glazier RH, Brent MH, Wong DT. Prevalence and predictors for being unscreened for diabetic retinopathy: a population-based study over a decade. Can J Ophthalmol. 2023 Aug;58(4):278–286. doi: 10.1016/j.jcjo.2022.04.002.Felfeli T, Katsnelson G, Kiss A, Plumptre L, Paterson JM, Ballios BG, Mandelcorn ED, Glazier RH, Brent MH, Wong DT. Prevalence and predictors for being unscreened for diabetic retinopathy: a population-based study over a decade. Can J Ophthalmol. 2023 Aug;58(4):278–286. doi: 10.1016/j.jcjo.2022.04.002.Campochiaro PA, Wykoff CC, Shapiro H, Rubio RG, Ehrlich JS. Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema. Ophthalmology 2014 Sep;121(9):1783–1789. doi: 10.1016/j.ophtha.2014.03.021.Campochiaro PA, Wykoff CC, Shapiro H, Rubio RG, Ehrlich JS. Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema. Ophthalmology 2014 Sep;121(9):1783–1789. doi: 10.1016/j.ophtha.2014.03.021.Arrigo A, Andrea Saladino A, Aragona E, Amato A, Capone L, Bianco L, Lattanzio R , Bandello F, Battaglia Parodi M. Foveal eversion patterns in diabetic macular edema. Sci Rep. 2022 Jul 30;12(1):13097. doi: 10.1038/s41598-022-17555-8.Arrigo A, Andrea Saladino A, Aragona E, Amato A, Capone L, Bianco L, Lattanzio R , Bandello F, Battaglia Parodi M. Foveal eversion patterns in diabetic macular edema. Sci Rep. 2022 Jul 30;12(1):13097. doi: 10.1038/s41598-022-17555-8.Campos A, Campos EJ, Martins J, Ambrósio AF, Silva R. Viewing the choroid: where we stand, challenges and contradictions in diabetic retinopathy and diabetic macular oedema. Acta Ophthalmol. 2017 Aug;95(5):446–459. doi: 10.1111/aos.13210.Campos A, Campos EJ, Martins J, Ambrósio AF, Silva R. Viewing the choroid: where we stand, challenges and contradictions in diabetic retinopathy and diabetic macular oedema. Acta Ophthalmol. 2017 Aug;95(5):446–459. doi: 10.1111/aos.13210.Framme C, Schweizer P, Imesch M. Behavior of SD-OCT — Detected Hyperreflective Foci in the Retina of Anti-VEGF — Treated Patients with Diabetic Macular Edema. Invest Ophthalmol Vis Sci. 2012 Aug 24;53(9):5814-8. doi: 10.1167/iovs.12-9950.Framme C, Schweizer P, Imesch M. Behavior of SD-OCT — Detected Hyperreflective Foci in the Retina of Anti-VEGF — Treated Patients with Diabetic Macular Edema. Invest Ophthalmol Vis Sci. 2012 Aug 24;53(9):5814-8. doi: 10.1167/iovs.12-9950.Phadikar P, Saxena S, Ruia S, Lai TY, Meyer CH, Eliott D. The potential of spectral domain optical coherence tomography imaging based retinal biomarkers. Int J Retina Vitreous. 2017 Jan 9;3:1. doi: 10.1186/s40942-016-0054-7.Phadikar P, Saxena S, Ruia S, Lai TY, Meyer CH, Eliott D. The potential of spectral domain optical coherence tomography imaging based retinal biomarkers. Int J Retina Vitreous. 2017 Jan 9;3:1. doi: 10.1186/s40942-016-0054-7.Pelosini L, Hull CC, Boyce JF, McHugh D, Stanford MR, Marshall J. . Optical Coherence Tomography May Be Used to Predict Visual Acuity in Patients with Macular Edema. Invest Ophthalmol Vis Sci 2011 Apr 25;52(5):2741–2748. doi: 10.1167/iovs.09-4493.Pelosini L, Hull CC, Boyce JF, McHugh D, Stanford MR, Marshall J. . Optical Coherence Tomography May Be Used to Predict Visual Acuity in Patients with Macular Edema. Invest Ophthalmol Vis Sci 2011 Apr 25;52(5):2741–2748. doi: 10.1167/iovs.09-4493.Shin H, Lee S, Chung H, Kim H. Association between photoreceptor integrity and visual outcome in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2012 Jan;250(1):61–70. doi: 10.1007/s00417-011-1774-x.Shin H, Lee S, Chung H, Kim H. Association between photoreceptor integrity and visual outcome in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2012 Jan;250(1):61–70. doi: 10.1007/s00417-011-1774-x.Chakravarthy U, Yang Y, Lotery A, Ghanchi F, Bailey C, Holz F, Downey L, Weber M, Eter N, Dugel P. Clinical evidebce of the multifactorial nature of diabetic macular edema. Retina. 2018 Feb;38(2):343–351. doi: 10.1097/IAE.0000000000001555.Chakravarthy U, Yang Y, Lotery A, Ghanchi F, Bailey C, Holz F, Downey L, Weber M, Eter N, Dugel P. Clinical evidebce of the multifactorial nature of diabetic macular edema. Retina. 2018 Feb;38(2):343–351. doi: 10.1097/IAE.0000000000001555.Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, Brucker AJ, Ferris FL, Hampton GR, Jhaveri C, Melia M, Beck RW. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial Ophthalmology. 2016 Jun;123(6):1351–1359. doi: 10.1016/j.ophtha.2016.02.022.Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, Brucker AJ, Ferris FL, Hampton GR, Jhaveri C, Melia M, Beck RW. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial Ophthalmology. 2016 Jun;123(6):1351–1359. doi: 10.1016/j.ophtha.2016.02.022.Coughlin BA, Feenstra DJ, Mohr S. Müller cells and diabetic retinopathy. Vis. Res. . 2017 Oct:139:93–100. doi: 10.1016/j.visres.2017.03.013.Coughlin BA, Feenstra DJ, Mohr S. Müller cells and diabetic retinopathy. Vis. Res. . 2017 Oct:139:93–100. doi: 10.1016/j.visres.2017.03.013.Das A, McGuire PG, Rangasamy S. Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmology. 2015;122(7):1375–1394. doi: 10.1016/j.ophtha.2015.03.024.Das A, McGuire PG, Rangasamy S. Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmology. 2015;122(7):1375–1394. doi: 10.1016/j.ophtha.2015.03.024.Zhang X, Zeng H, Bao S, Wang N, Gillies MC. Diabetic macular edema: new concepts in patho-physiology and treatment. Cell Biosci. 2014 May 14:4:27. doi: 10.1186/2045-3701-4-27.Zhang X, Zeng H, Bao S, Wang N, Gillies MC. Diabetic macular edema: new concepts in patho-physiology and treatment. Cell Biosci. 2014 May 14:4:27. doi: 10.1186/2045-3701-4-27.Lai D, Wu Y, Shao C, Qiu Q. The Role of Müller Cells in Diabetic Macular Edema. Invest Ophthalmol Vis Sci. 2023 Jul 3;64(10):8. doi: 10.1167/iovs.64.10.8.Lai D, Wu Y, Shao C, Qiu Q. The Role of Müller Cells in Diabetic Macular Edema. Invest Ophthalmol Vis Sci. 2023 Jul 3;64(10):8. doi: 10.1167/iovs.64.10.8.Reichenbach A, Bringmann A. Glia of the human retina. Glia. 2020 Apr;68(4):768–796. doi: 10.1002/glia.23727.Reichenbach A, Bringmann A. Glia of the human retina. Glia. 2020 Apr;68(4):768–796. doi: 10.1002/glia.23727.Kiire CA, Broadgate S, Halford S, Chong V. Diabetic macular edema with foveal eversion shows a distinct cytokine profile to other forms of diabetic macular edema in patients with type 2 diabetes. Investigative Ophthalmology & Visual Science April. 2014;55:4408.Kiire CA, Broadgate S, Halford S, Chong V. Diabetic macular edema with foveal eversion shows a distinct cytokine profile to other forms of diabetic macular edema in patients with type 2 diabetes. Investigative Ophthalmology & Visual Science April. 2014;55:4408.Shah AR, Yonekawa Y, Todorich B, Van Laere L, Hussain R, Woodward MA, Abbey AM, Wolfe JD. Prediction of Anti-VEGF Response in Diabetic Macular Edema After 1 Injection. J Vitreoretin Dis. 2017 May;1(3):169–174. doi: 10.1177/2474126416682569.Shah AR, Yonekawa Y, Todorich B, Van Laere L, Hussain R, Woodward MA, Abbey AM, Wolfe JD. Prediction of Anti-VEGF Response in Diabetic Macular Edema After 1 Injection. J Vitreoretin Dis. 2017 May;1(3):169–174. doi: 10.1177/2474126416682569.Tan GS, Cheung N, Simó R, Cheung GC, Wong TY. Diabetic macular oedema. Lancet Diabetes Endocrinol. 2017 Feb;5(2):143–155. doi: 10.1016/S2213-8587(16)30052-3.Tan GS, Cheung N, Simó R, Cheung GC, Wong TY. Diabetic macular oedema. Lancet Diabetes Endocrinol. 2017 Feb;5(2):143–155. doi: 10.1016/S2213-8587(16)30052-3.

The authors declare that there are no conflicts of interest present.